Overview

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Status:
Recruiting

Trial end date:
2023-10-11

Target enrollment:

Participant gender:

Summary

This trial is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of first-line chemo-immunotherapy combinations in participants with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Phase:

Phase 1

Details

Lead Sponsor:

Parker Institute for Cancer Immunotherapy

Collaborators:

Bristol-Myers Squibb
Cancer Research Institute, New York City

Treatments:

Gemcitabine
Hydroxychloroquine
Ipilimumab
Nivolumab
Paclitaxel